Kevin Lee

TL;DR: The key protein families that mediate epigenetic signalling through the acetylation and methylation of histones are reviewed, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones.

TL;DR: It is demonstrated that the first small-molecule catalytic site inhibitor that is selective for the H3K27me3-specific JMJ subfamily binds in a novel manner and reduces lipopolysaccharide-induced proinflammatory cytokine production by human primary macrophages, a process that depends on both JMJD3 and UTX.

TL;DR: The structure-based design of a highly selective inhibitor of the CREB binding protein (CBP) bromodomain is described and its use in cell-based transcriptional profiling experiments is described, suggesting a potential therapeutic opportunity for CBP inhibitors in the treatment of neurological disorders.

TL;DR: The accompanying Comment by Heinemann et al., in which the authors use an extensive panel of sensitive KDM assays to independently confirm the authors' results that GSK-J1 is a potent KDM6 inhibitor, shows that G SKD1 remains the most selective KDM inhibitor yet disclosed and thus a valuable chemical tool.

TL;DR: A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of the bromodomain-containing protein: ATAD2 is described in this article.